Movers & Shakers - Spark Newswire

1 minute read

Spectrum Gets FDA Nod For Febrile Neutropenia Candidate, Sees Commercial Launch In Q4 2022

Today, 10:08 PM

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ: SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia.

SPPI

1 minute read

Rhythm Secures European Commission Marketing Authorization For Genetic Disease Candidate

By Ragothaman Srinivasan

Today, 10:08 PM

The European Commission (EC) has expanded the marketing authorization for Rhythm’s (NASDAQ: RYTM) lead drug product IMCIVREE (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) in adult and pediatric patients 6 years of age an

RYTM

2 minute read

Iveric Bio Shares Shoot Higher Following Positive Top-line Data From Late-Stage Geographic Atrophy Study

By Ragothaman Srinivasan

Today, 10:08 PM

Iveric Bio (NASDAQ: ISEE) announced positive topline results from the second Phase 3 clinical trial of Zimura (avacincaptad pegol) for the treatment of geographic atrophy (GA).

ISEE

3 minute read

Lantern Bolsters Board With Columbia Care VP, Verano Taps M&A Pro, And Other Key Exec Moves

By Jelena Martinovic

Today, 10:08 PM

Top CEOs, investors and leaders in the cannabis industry will soon convene at the Benzinga Cannabis Capital Conference on Sept. 13-14 in Chicago.

CCHWF

3 minute read

Warren Buffett Turns 92: A Highlight For Each Decade Of His Life

By Chris Katje

Today, 10:08 PM

Legendary investor Warren Buffett was born Aug. 30, 1930. The “Oracle of Omaha” turns 92 today and has lived through 10 decades.

AAL

2 minute read

Strategic Leadership Changes At Cannabis Firms: What’s New At Vertosa, Rubicon And Galexxy

By Jelena Martinovic

Today, 10:08 PM

Top CEOs, investors and leaders in the cannabis industry will soon convene at the Benzinga Cannabis Capital Conference on Sept. 13-14 in Chicago.

GXXY

1 minute read

Inhibikase Shares Shoot Higher As FDA Announced Clearance To Blood-Cell Cancer Study

By Ragothaman Srinivasan

Today, 10:08 PM

The U.S. Food and Drug Administration (FDA) has reviewed Inhibikase Therapeutics’ (NASDAQ: IKT) Investigational New Drug (IND) application and issued a Study May Procced (SMP) letter for its drug candidate IkT-001Pro in the treatment of Chronic Myelogenous Leukemia (CML).

IKT

1 minute read

Apellis Shares Show Mixed Reaction After Positive 2 Years Data From Late-Stage Retinal Disorder Study

By Ragothaman Srinivasan

Today, 10:08 PM

Apellis Pharmaceuticals (NASDAQ: APLS) revealed top-line data readout at 24 months showing increased effects over time with intravitreal pegcetacoplan in the Phase 3 DERBY and OAKS studies in geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

APLS

1 minute read

KalVista Shares Climb As Late-Stage Label Extension Study On Skin Disorder Candidate Kicks-off

By Ragothaman Srinivasan

Today, 10:08 PM

KalVista Pharmaceuticals (NASDAQ: KALV) has initiated the KONFIDENT-S open label extension (OLE) study for its ongoing Phase 3 study of sebetralstat for the on-demand treatment of hereditary angioedema (HAE) attacks.

KALV

1 minute read

Cue Biopharma Shares Decline Following Initial-Stage Metastatic Cancer Study Kicks-off

By Ragothaman Srinivasan

Today, 10:08 PM

Cue Biopharma (NASDAQ: CUE) has dosed the first patient in a Phase 1 dose escalation study evaluating CUE-102 for the treatment of patients with Wilms' Tumor 1 (WT1)-positive recurrent/metastatic cancers.

CUE